Browsing by Author "Renemane, Ļubova"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    MENTAL DISORDERS FOLLOWING COVID-19 INFECTION : A SYSTEMATIC REVIEW OF ACUTE AND LONG-TERM PSYCHIATRIC MANIFESTATIONS AND ASSOCIATED BRAIN CHANGES
    (2020) Fischer, Paale Ruben; Renemane, Ļubova; Rīga Stradiņš University
    The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily affects the respiratory tract, but sometimes also other organs, including the central nervous system (CNS). It is not well understood how the virus affects the CNS and how frequently it happens. Our review provides insight into the occurrence of mental disorders in Corona Virus Disease 2019 (COVID-19) patients. We also collected information about the biological basis of the susceptibility of brain cells to SARS-CoV-2 and its implication to psychiatric manifestations. We included 24 publications in our review, reporting psychiatric manifestations published between 31 December 2019 and 30 July 2020, using the Preferred Reporting Items for Systemic Review and Meta-Analysis statement. Mental disorders occurred in up to one-fifth of patients during the acute phase of the infection. The most common disorders included anxiety-related disorders, mood-spectrum disorders, impaired consciousness, confusion, delirium and psychosis. The onset of psychiatric manifestations is not always preceded by respiratory symptoms, but occurs initially in COVID-19 patients. Long-term manifestations are mainly depression and post-traumatic stress symptoms. The obtained data allow the statement that direct infection of the CNS by SARS-CoV-2 could be responsible for the observed findings. To further investigate long-term psychiatric manifestations, randomised controlled studies must be initiated.
  • No Thumbnail Available
    Item
    New-onset psychosis following COVID-19 vaccination : a systematic review
    (2024) Lazareva, Marija; Renemane, Ļubova; Vrubļevska, Jeļena; Rancāns, Elmārs; Department of Psychiatry and Narcology
    Background: The emergence of a new coronavirus strain caused the COVID-19 pandemic. While vaccines effectively control the infection, it’s important to acknowledge the potential for side effects, including rare cases like psychosis, which may increase with the rising number of vaccinations. Objectives: Our systematic review aimed to examine cases of new-onset psychosis following COVID-19 vaccination. Methods: We conducted a systematic review of case reports and case series on new-onset psychosis following COVID-19 vaccination from December 1st, 2019, to November 21st, 2023, using PubMed, MEDLINE, ClinicalKey, and ScienceDirect. Data extraction covered study and participant characteristics, comorbidities, COVID-19 vaccine details, and clinical features. The Joanna Briggs Institute quality assessment tools were employed for included studies, revealing no significant publication bias. Results: A total of 21 articles described 24 cases of new-onset psychotic symptoms following COVID-19 vaccination. Of these cases, 54.2% were female, with a mean age of 33.71 ± 12.02 years. Psychiatric events were potentially induced by the mRNA BNT162b2 vaccine in 33.3% of cases, and psychotic symptoms appeared in 25% following the viral vector ChAdOx1 nCoV-19 vaccine. The mean onset time was 5.75 ± 8.14 days, mostly reported after the first or second dose. The duration of psychotic symptoms ranged between 1 and 2 months with a mean of 52.48 ± 60.07 days. Blood test abnormalities were noted in 50% of cases, mainly mild to moderate leukocytosis and elevated C-reactive protein. Magnetic resonance imaging results were abnormal in 20.8%, often showing fluid-attenuated inversion recovery hyperintensity in the white matter. Treatment included atypical antipsychotics in 83.3% of cases, typical antipsychotics in 37.5%, benzodiazepines in 50%, 20.8% received steroids, and 25% were prescribed antiepileptic medications. Overall, 50% of patients achieved full recovery. Conclusion: Studies on psychiatric side effects post-COVID-19 vaccination are limited, and making conclusions on vaccine advantages or disadvantages is challenging. Vaccination is generally safe, but data suggest a potential link between young age, mRNA, and viral vector vaccines with new-onset psychosis within 7 days post-vaccination. Collecting data on vaccine-related psychiatric effects is crucial for prevention, and an algorithm for monitoring and treating mental health reactions post-vaccination is necessary for comprehensive management. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42023446270.
  • No Thumbnail Available
    Item
    Sertraline induced acute hepatocellular liver injury in patient with major depressive disorder : a case report
    (2024-08-01) Renemane, Ļubova; Rancāns, Elmārs; Department of Psychiatry and Narcology
    This case report describes a patient with major depressive disorder (MDD) who developed acute hepatocellular liver injury after being treated with sertraline, a selective serotonin reuptake inhibitor (SSRI). The diagnosis of MDD was made two years prior, and the patient had previously responded partially to escitalopram and cognitive-behavioral therapy (CBT). Upon switching to sertraline 50 mg daily, the patient presented with severe symptoms indicative of acute liver injury, including elevated liver enzymes, jaundice, and gastrointestinal distress. Following the discontinuation of sertraline, the patient’s liver function tests gradually normalized over a 90-day period, confirming the diagnosis of sertraline-induced hepatotoxicity. This case underscores the importance of continuous monitoring for potential liver injury in patients treated with sertraline. The findings contribute to the existing body of evidence on the hepatotoxic risks associated with SSRIs and highlight the need for personalized treatment strategies to mitigate adverse effects and enhance patient safety. Further research is needed to explore the long-term safety and efficacy of sertraline, particularly in vulnerable populations.